Epithalon mastery course
Unit 10 of 12
Safety & side effects
Epitalon’s published safety record looks quiet, with few severe acute events in studied cohorts, but that calm is thin.…
What is reported, what is unknown, and the market reality
Epitalon’s published safety record looks quiet, with few severe acute events in studied cohorts, but that calm is thin. This unit separates the reassuring parts from the real gaps: unknown long-horizon oncologic and endocrine effects, injection risks, and above all a gray-market supply where identity and purity cannot be assumed.
It closes on the regulatory reality across the US, Europe, and sport, because for most people the biggest safety variable is not the peptide’s biology but the product and the law.